-
NDA filing of Acute Migraine Treatment by Dr. Reddy’s Laboratories and Promius Pharma
- April 2, 2018
- Posted by: PharmaScroll
- Category:
No Comments -
Ocrevus shows higher efficacy than Rebif on NEDA in RRMS patients, a recent analysis shows
- April 2, 2018
- Posted by: PharmaScroll
- Category:
-
sTMS Device can prevent Migraine attacks, claims a recent observational study
- April 2, 2018
- Posted by: PharmaScroll
- Category:
-
FLX-787 in Multiple Sclerosis displays positive Phase 2 Topline results
- March 28, 2018
- Posted by: PharmaScroll
- Category:
-
Successful results for Multiple Sclerosis MAb GNbAC1 announced by GeNeuro and Servier in Phase 2b CHANGE-MS Study
- March 27, 2018
- Posted by: PharmaScroll
- Category:
-
Acute Migraine treatment Rimegepant successfully achieves Co-Primary Endpoints in two pivotal Phase 3 Trials
- March 26, 2018
- Posted by: PharmaScroll
- Category:
-
Secondary Progressive MS – Pharmascroll Report predicts increase in market activity in next 5-10 years
- March 26, 2018
- Posted by: PharmaScroll
- Category:
Expected launch of Siponimod and a strong pipeline in SPMS indicates a strong SPMS focus. SPMS- Detailed overview provides an overview of SPMS in detail, highlights the SPMS epidemiology, elaborates on the drugs prescribed and expected to be prescribed along with the sales and patient numbers forecast.
-
Low risk of serotonin syndrome associated with concomitant use of triptans and SSRIs or SNRIs, finds latest study
- March 24, 2018
- Posted by: PharmaScroll
- Category:
-
Siponimod significantly improves patient outcomes in SPMS, as per latest study
- March 23, 2018
- Posted by: PharmaScroll
- Category:
-
Clinical outcomes assessed for older patients discontinuing MS DMTs
- March 23, 2018
- Posted by: PharmaScroll
- Category:
enquiry@pharmascroll.com
Mail Us
enquiry@pharmascroll.com
Mail Us